Nanoparticle-mediated delivery of anticancer agents to tumor angiogenic vessels

Biological and Pharmaceutical Bulletin

Volumn 35, Issue 11, 2012, Pages 1855-1861

  Asai, Tomohiro ^a  

^a UNIVERSITY OF SHIZUOKA   (Japan)

Author keywords

Angiogenic vessel targeting; Anticancer drug; Liposome; Nanoparticle; Peptide; Small interfering RNA

Indexed keywords

5' O DIPALMITOYLPHOSPHATIDYL 2' C CYANO 2' DEOXY 1 BETA DEXTRO ARABINO PENTOFURANOSYLCYTOSINE; ALANYLPROLYLARGINYLPROLYLGLYCINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME; MACROGOL; NANOPARTICLE; PEPTIDE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN INHIBITOR;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER RESEARCH; COLON CARCINOMA; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG RELEASE; DRUG RETENTION; ENDOTHELIUM CELL; HUMAN; LIPOSOMAL GENE DELIVERY SYSTEM; MALIGNANT NEOPLASTIC DISEASE; NANOENCAPSULATION; NONHUMAN; PANCREAS CANCER; PROTEIN TARGETING; REVIEW; SARCOMA; TUMOR MICROENVIRONMENT;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG CARRIERS; HUMANS; NANOPARTICLES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84869209158     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.b212013     Document Type: Review

References (29)

1. Min JH, Lee HY, Lim H, Ahn MJ, Park K, Chung MP, Lee KS. Drug-induced interstitial lung disease in tyrosine kinase inhibitor therapy for non-small cell lung cancer: a review on current insight. Cancer Chemother. Pharmacol., 68, 1099-1109 (2011).
2. Schroeder A, Heller DA, Winslow MM, Dahlman JE, Pratt GW, Langer R, Jacks T, Anderson DG. Treating metastatic cancer with nanotechnology. Nat. Rev. Cancer, 12, 39-50 (2012).
3. Burnett JC, Rossi JJ, Tiemann K. Current progress of siRNA/shRNA therapeutics in clinical trials. Biotechnol. J., 6, 1130-1146 (2011).
4. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res., 46, 6387-6392 (1986).
5. Seki T, Fang J, Maeda H. Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci., 100, 2426-2430 (2009).
6. Nakamura K, Abu Lila AS, Matsunaga M, Doi Y, Ishida T, Kiwada H. A double-modulation strategy in cancer treatment with a chemotherapeutic agent and siRNA. Mol. Ther., 19, 2040-2047 (2011).
7. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat. Rev. Drug Discov., 6, 273-286 (2007).
8. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science, 307, 58-62 (2005).
9. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature, 473, 298-307 (2011).
10. Shojaei F. Anti-angiogenesis therapy in cancer: current challenges and future perspectives. Cancer Lett., 320, 130-137 (2012).
11. Pàez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Viñals F, Inoue M, Bergers G, Hanahan D, Casanovas O. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell, 15, 220-231 (2009).
12. Oku N, Asai T, Watanabe K, Kuromi K, Nagatsuka M, Kurohane K, Kikkawa H, Ogino K, Tanaka M, Ishikawa D, Tsukada H, Momose M, Nakayama J, Taki T. Anti-neovascular therapy using novel peptides homing to angiogenic vessels. Oncogene, 21, 2662-2669 (2002).
13. Asai T, Shimizu K, Kondo M, Kuromi K, Watanabe K, Ogino K, Taki T, Shuto S, Matsuda A, Oku N. Anti-neovascular therapy by liposomal DPP-CNDAC targeted to angiogenic vessels. FEBS Lett., 520, 167-170 (2002).
14. Kondo M, Asai T, Katanasaka Y, Sadzuka Y, Tsukada H, Ogino K, Taki T, Baba K, Oku N. Anti-neovascular therapy by liposomal drug targeted to membrane type-1 matrix metalloproteinase. Int. J. Cancer, 108, 301-306 (2004).
15. Shimizu K, Asai T, Fuse C, Sadzuka Y, Sonobe T, Ogino K, Taki T, Tanaka T, Oku N. Applicability of anti-neovascular therapy to drug-resistant tumor: suppression of drug-resistant P388 tumor growth with neovessel-targeted liposomal adriamycin. Int. J. Pharm., 296, 133-141 (2005).
16. Atobe K, Ishida T, Ishida E, Hashimoto K, Kobayashi H, Yasuda J, Aoki T, Obata K, Kikuchi H, Akita H, Asai T, Harashima H, Oku N, Kiwada H. In vitro efficacy of a sterically stabilized immunoliposomes targeted to membrane type 1 matrix metalloproteinase (MT1-MMP). Biol. Pharm. Bull., 30, 972-978 (2007).
17. Yonezawa S, Asai T, Oku N. Effective tumor regression by antineovascular therapy in hypovascular orthotopic pancreatic tumor model. J. Control. Release, 118, 303-309 (2007).
18. Asai T, Miyazawa S, Maeda N, Hatanaka K, Katanasaka Y, Shimizu K, Shuto S, Oku N. Antineovascular therapy with angiogenic vessel-targeted polyethyleneglycol-shielded liposomal DPP-CNDAC. Cancer Sci., 99, 1029-1033 (2008).
19. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. Int. J. Cancer, 127, 2685-2698 (2010).
20. Murase Y, Asai T, Katanasaka Y, Sugiyama T, Shimizu K, Maeda N, Oku N. A novel DDS strategy, "dual-targeting," and its application for antineovascular therapy. Cancer Lett., 287, 165-171 (2010).
21. Katanasaka Y, Ida T, Asai T, Maeda N, Oku N. Effective delivery of an angiogenesis inhibitor by neovessel-targeted liposomes. Int. J. Pharm., 360, 219-224 (2008).
22. Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N. Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. Cancer Lett., 270, 260-268 (2008).
23. Asai T, Matsushita S, Kenjo E, Tsuzuku T, Yonenaga N, Koide H, Hatanaka K, Dewa T, Nango M, Maeda N, Kikuchi H, Oku N. Dicetyl phosphate- tetraethylenepentamine-based liposomes for systemic siRNA delivery. Bioconjug. Chem., 22, 429-435 (2011).
24. Koide H, Asai T, Furuya K, Tsuzuku T, Kato H, Dewa T, Nango M, Maeda N, Oku N. Inhibition of Akt (ser473) phosphorylation and rapamycin-resistant cell growth by knockdown of mammalian target of rapamycin with small interfering RNA in vascular endothelial growth factor receptor-1-targeting vector. Biol. Pharm. Bull., 34, 602-608 (2011).
25. St Croix B, Rago C, Velculescu V, Traverso G, Romans KE, Montgomery E, Lal A, Riggins GJ, Lengauer C, Vogelstein B, Kinzler KW. Genes expressed in human tumor endothelium. Science, 289, 1197-1202 (2000).
26. Maeda N, Takeuchi Y, Takada M, Sadzuka Y, Namba Y, Oku N. Anti-neovascular therapy by use of tumor neovasculature-targeted long-circulating liposome. J. Control. Release, 100, 41-52 (2004).
27. Maeda N, Miyazawa S, Shimizu K, Asai T, Yonezawa S, Kitazawa S, Namba Y, Tsukada H, Oku N. Enhancement of anticancer activity in antineovascular therapy is based on the intratumoral distribution of the active targeting carrier for anticancer drugs. Biol. Pharm. Bull., 29, 1936-1940 (2006).
28. Hollebecque A, Massard C, Soria JC. Vascular disrupting agents: a delicate balance between efficacy and side effects. Curr. Opin. Oncol., 24, 305-315 (2012).
29. Asai T, Suzuki Y, Matsushita S, Yonezawa S, Yokota J, Katanasaka Y, Ishida T, Dewa T, Kiwada H, Nango M, Oku N. Disappearance of the angiogenic potential of endothelial cells caused by Argonaute2 knockdown. Biochem. Biophys. Res. Commun., 368, 243-248 (2008).